Axatilimab
- Generic Name
- Axatilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2155851-88-8
- Unique Ingredient Identifier
- R96Z451BMC
- Background
Axatilimab is under investigation in clinical trial NCT04301778 (Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-embolization for Patients With Intrahepatic Cholangiocarcinoma).
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 41
- Registration Number
- NCT03604692
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of Minnesota Medical Center, Minneapolis, Minnesota, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT03238027
- Locations
- 🇺🇸
Honor Health, Scottsdale, Arizona, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath